![Figure 2: Preemptive combinations. (A) EGFR-Mutant-Driven NSCLC. See text. (B) METex14-Driven NSCLC. See text.](https://www.oncotarget.net/wp-content/uploads/2024/03/Screen-Shot-2024-03-19-at-8.39.43-AM-300x171.png)
“From Osimertinib to Preemptive Combinations” by Dr. Blagosklonny
March 19, 2024
Here I will re-introduce the notion of preemptive combinations (PC) of targeted drugs.”BUFFALO, NY- March 19, 2024 – A new research perspective was published by Mikhail V. Blagosklonny M.D.,... read more